Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)

• DOI: 10.1007/s12149-018-1230-7
• Publication Date: 2018-01-15T01:32:47Z
• Authors: Makoto Hosono; Hideharu Ikebuchi; Yoshihide Nakamura; Nobutaka Nakamura; Takahiro Yamada; Sachiko Yanagida; Asami Kitaoka; Kiyotaka Kojima; Hiroyasu Sugano; Seigo Kinuya; Tomio Inoue; Jun Hatazawa
• Keywords: Health Personnel; Lutetium; 3. Good health; Manuals as Topic; Neuroendocrine Tumors; 03 medical and health sciences; Radiation Protection; 0302 clinical medicine; Japan; Report; Practice Guidelines as Topic; Humans; Nuclear Medicine; Radiopharmaceuticals; Safety

Here we present the guideline for the treatment of neuroendocrine tumors using Lu-177-DOTA-TATE on the basis of radiation safety aspects in Japan. This guideline was prepared by a study supported by Ministry of Health, Labour, and Welfare, and approved by Japanese Society of Nuclear Medicine. Lu-177-DOTA-TATE treatment in Japan should be carried out according to this guideline. Although this guideline is applied in Japan, the issues for radiation protection shown in this guideline are considered internationally useful as well. Only the original Japanese version is the formal document.